Beijing Sun-Novo Pharmaceutical Research Valuation

Q: What is the Fair Price of 688621 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

688621 (CN¥40.7) is trading above our estimate of [[fair value]] (CN¥24.86)

Is 688621 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688621 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688621 (CN¥40.7) is trading above our estimate of fair value (CN¥24.86)

Significantly Below Fair Value: 688621 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688621?

Key metric: As 688621 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 688621. This is calculated by dividing 688621's market cap by their current earnings.
What is 688621's PE Ratio?
PE Ratio	20.6x
Earnings	CN¥221.37m
Market Cap	CN¥4.56b

688621 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.8x
Enterprise Value/EBITDA	16.6x
PEG Ratio	0.7x

Price to Earnings Ratio vs Peers

How does 688621's PE Ratio compare to its peers?

The above table shows the PE ratio for 688621 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	43x
301096 Hangzhou Bio-Sincerity Pharma-TechLtd	20.5x	33.3%	CN¥4.3b
300404 Boji Medical TechnologyLtd	75.9x	39.2%	CN¥3.3b
688710 Shanghai Innostar Biotechnology	37.3x	n/a	CN¥5.5b
688046 GemPharmatech	38.3x	27.9%	CN¥5.3b
688621 Beijing Sun-Novo Pharmaceutical Research	20.6x	29.5%	CN¥4.6b

Price-To-Earnings vs Peers: 688621 is good value based on its Price-To-Earnings Ratio (20.6x) compared to the peer average (42.3x).

Price to Earnings Ratio vs Industry

How does 688621's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 688621 is good value based on its Price-To-Earnings Ratio (20.6x) compared to the Asian Life Sciences industry average (31.9x).

Price to Earnings Ratio vs Fair Ratio

What is 688621's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688621 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	20.6x
Fair PE Ratio	28.1x

Price-To-Earnings vs Fair Ratio: 688621 is good value based on its Price-To-Earnings Ratio (20.6x) compared to the estimated Fair Price-To-Earnings Ratio (28.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥48.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥30.51

2.2%

7.6%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.59

-2.4%

12.8%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.91

-1.8%

14.6%